

CURRICULUM VITAE

Name: Ziyu Li
Address: Gastrointestinal Surgery Center, Peking University Cancer Hospital, 52 Fucheng Rd., Haidian District, Beijing 100142, China
Tel: +8610-88196605
Email: ligregory@outlook.com
Current Position: Professor & Chief Surgeon in gastrointestinal surgery, President & Deputy Party Committee Secretary, Peking University Cancer Hospital & Beijing Institute for Cancer Research.
Medical License No.: 110110000018623

EDUCATION, POSTDOCTORAL TRAINING & WORK EXPERIENCE:

1995 M.D., Qingdao Medical College, Qingdao, China.
2002 Ph.D., Tongji Medical College, Huazhong Science and Technology University, Wuhan, China
1995-1999 Resident Training, Department of Hepatobiliary Surgery, Qingdao Municipal Hospital, Qingdao, China.
2001-2002 Attending Surgeon, Department of General Surgery, Tongji Hospital, Wuhan, China.
2002-2005 Postdoctoral Training, Department of GI Cancer Surgery, Beijing Cancer Hospital, Beijing, China.
2005.8-2012.7 Deputy Chief Surgeon, Department of GI Cancer Surgery, Beijing Cancer Hospital, Beijing, China.
2009.7-2009.11 International fellow, Colorectal Unit at Concord Hospital, University of Sydney, Australia.
2010.8-2015.7 Associate Professor, Department of GI Cancer Surgery, Beijing Cancer Hospital, Beijing, China.
2012.7-2015.7 Deputy Director of General Surgery, Chief Surgeon, Associate Professor, Beijing Cancer Hospital
2015.8-present Professor, Beijing Cancer Hospital
2015.7-2016.6 Deputy Director of General Surgery, Director of GI Surgery Center Unit 1, Beijing Cancer Hospital
2016.6-2022.6 President Assistant, Deputy Director of General Surgery, Director of GI Surgery Center Unit 1, Beijing Cancer Hospital
2022.6-present President & Deputy Party Committee Secretary, Beijing Cancer Hospital, Peking University Cancer Hospital, Peking University School of Oncology, Beijing Institute for Cancer Research

CURRENT POSITION IN PROFESSIONAL SOCIETIES:

China Anti-Cancer Association	Vice President
Chinese Gastric Cancer Association (CGCA)	Vice President

Society of MDT Cancer Care, China Anti-Cancer Association	Vice President
GI Surgery Group, Chinese Society of Surgery, Chinese Medical Association	Member
The Eighth Council, Beijing Anti-Cancer Association	Executive Director
Beijing Association of Oncology	Vice President
Gastric Cancer Committee, Beijing Association of Oncology	Chairman-elect

SELECTED PUBLICATIONS:

1. Zhang X#, Liang H#, **Li Z#**, Xue Y#, Wang Y, Zhou Z, Yu J, Bu Z, Chen L, Du Y, Wang X, Wu A, Li G, Su X, Xiao G, Cui M, Wu D, Chen L, Wu X, Zhou Y, Zhang L, Dang C, He Y, Zhang Z, Sun Y, Li Y, Chen H, Bai Y, Qi C, Yu P, Zhu G, Suo J, Jia B, Li L, Huang C, Li F, Ye Y, Xu H, Wang X, Yuan Y, E JY, Ying X, Yao C, Shen L, Ji J; RESOLVE study group. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. **Lancet Oncol.** 2021 Aug;22(8):1081-1092.
2. **Li Z**, Shan F, Ying X, Zhang Y, E JY, Wang Y, Ren H, Su X, Ji J. Assessment of Laparoscopic Distal Gastrectomy After Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer: A Randomized Clinical Trial. **JAMA Surg.** 2019 Dec 1;154(12):1093-1101.
3. **Li Z**, Gao X, Peng X, May Chen MJ, Li Z, Wei B, Wen X, Wei B, Dong Y, Bu Z, Wu A, Wu Q, Tang L, Li Z, Liu Y, Zhang L, Jia S, Zhang L, Shan F, Zhang J, Wu X, Ji X, Ji K, Wu X, Shi J, Xing X, Wu J, Lv G, Shen L, Ji X, Liang H, Ji J. Multi-omics characterization of molecular features of gastric cancer correlated with response to neoadjuvant chemotherapy. **Sci Adv.** 2020 Feb 26;6(9):eaay4211.
4. Dong D#, Tang L#, **Li ZY#**, Fang MJ, Gao JB, Shan XH, Ying XJ, Sun YS, Fu J, Wang XX, Li LM, Li ZH, Zhang DF, Zhang Y, Li ZM, Shan F, Bu ZD, Tian J, Ji JF. Development and validation of an individualized nomogram to identify occult peritoneal metastasis in patients with advanced gastric cancer. **Ann Oncol.** 2019 Mar 1;30(3):431-438.
5. **Li Z**, Wang Y, Shan F, Ying X, Wu Z, Xue K, Miao R, Zhang Y, Ji J. ypTNM staging after neoadjuvant chemotherapy in the Chinese gastric cancer population: an evaluation on the prognostic value of the AJCC eighth edition cancer staging system. **Gastric Cancer.** 2018 Nov;21(6):977-987.
6. **Li Z**, Li S, Ying X, Zhang L, Shan F, Jia Y, Ji J. The clinical value and usage of inflammatory and nutritional markers in survival prediction for gastric cancer patients with neoadjuvant chemotherapy and D2 lymphadenectomy. **Gastric Cancer.** 2020 May;23(3):540-549.